High grade serous ovarian cancer is characterized by genomic instability, with ~50% of advanced tumors harboring homologous recombination repair (HRR) pathway deficiency (HRD). HRD results in ...
Homologous Recombination Deficiency (HRD) is a biomarker that predicts ovarian cancer treatment with PARP inhibitors or breast cancer treatment with first-line platinum-based chemotherapy. However, ...
Homologous recombination deficiency (HRD) is a well-described phenotype of some prostate cancers; however, current biomarkers for HRD are imperfect and rely on detection of single gene alterations in ...
Ovarian cancer is the fifth-leading cause of cancer deaths among women, accounting for more deaths than any other cancer of the female reproductive system. The high mortality rate is mainly because ...
Disclaimer: AAAS and EurekAlert! are not responsible for the accuracy of news releases posted to EurekAlert! by contributing institutions or for the use of any information through the EurekAlert ...
SOFIVA GENOMICS has been continuously devoted to the research and development of cancer-based precision medicine. In a technological collaboration with the world-renowned SOPHiA GENETICS in 2022, ...
BOSTON & LAUSANNE, Switzerland--(BUSINESS WIRE)--SOPHiA GENETICS (Nasdaq: SOPH), a cloud-native software company in the healthcare space and a leader in data-driven medicine, today announced that ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback